Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve

This article was originally published in PharmAsia News

Executive Summary

In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services

You may also be interested in...



WuXi Venture Fund Managing Director Sofie Qiao On Taking Risks: An Interview With PharmAsia News

WuXi AppTec Inc. has largely invested along with established venture funds since its launch in 2011 backed by $50 million of investor funds. But the humble student aims to evolve and invest more boldly, says newly appointed managing director Sofie Qiao.

Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs

Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.

Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs

Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC076497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel